Stanford Medicine study: SARS-CoV-2 infects fat tissue, creates inflammatory storm cloud | News Center

Stanford Medicine study: SARS-CoV-2 infects fat tissue, creates inflammatory storm cloud | News Center

“Fat tissue’s susceptibility to SARS-CoV-2 infection may be playing a role in making obesity a COVID-19 risk factor,” said Blish, who is the George E. and Lucy Becker Professor in Medicine. “Infected fat tissue pumps out precisely the inflammatory chemicals you see in the blood of severe COVID patients. It’s reasonable to infer that having a lot of infected fat could contribute to the overall inflammatory profile of severely ill COVID-19 patients.”

The scientists obtained samples of fat tissue from various locations in the bodies of 22 patients undergoing bariatric or cardiothoracic surgery at the Stanford Medicine Bariatric Surgery and Cardiothoracic Surgery clinic.

Then, in a secure facility, the researchers infected the samples with a solution containing SARS-CoV-2 or, as a control, a SARS-CoV-2-free solution. Rigorous experiments showed that the virus could infect and replicate in fat cells, exit the cells and cause new infections in other cells.

Fat tissue contains not only fat cells but also a wide variety of immune cells, including a type called macrophages. These cells (whose name derives from two Greek words meaning “big eaters”) carry out a number of actions ranging from tissue repair and general garbage cleanup to fierce attacks on perceived pathogens — sometimes producing substantial collateral damage to normal tissue in the process.

The researchers identified a subset of macrophages in fat tissue that become infected by SARS-CoV-2, although only fleetingly. SARS-CoV-2 infection of these macrophages is abortive: It produces no viable viral progeny. But it does induce a major mood change in the macrophages.“Once infected, these macrophages not only become inflamed themselves but also secrete substances that call in more inflammatory immune cells, in addition to inducing inflammation in uninfected neighboring ‘bystander cells,’” Blish said.

Fat tissue surrounds our hearts, guts, kidneys and pancreases, which can be adversely affected by tissue inflammation. Ominously, the scientists found infection capable of driving inflammation in virtually every SARS-CoV-2-infected fat-tissue sample they collected and analyzed.

Genetic material encoding SARS-CoV-2 was almost invariably present in fat tissue from various bodily regions of eight patients who’d died of COVID-19. Examining tissue from two other deceased COVID-19 patients, the team saw an infiltration of inflammatory immune cells adjacent to infected fat cells in epicardial fat.

“This was of great concern to us, as epicardial fat lies right next to the heart muscle, with no physical barrier separating them,” McLaughlin said. “So, any inflammation there may directly affect the heart muscle or coronary arteries.”

Missing ACE2

Oddly, ACE2 — the cell surface molecule that’s been implicated as the cardinal receptor for SARS-CoV-2 — appeared to play little or no role in the ability of the virus to infect fat cells.

The method by which SARS-CoV-2 gains entry to fat cells and macrophages in fat tissue remains mysterious. The established primary mode of entry occurs when the virus ties up with a protein called ACE2 that sits on cell surfaces in numerous bodily tissues. Although ACE2 carries out important, legitimate functions, the virus doesn’t care what ACE2 does for a living — it considers this cell-surface protein a mere docking station.

This was the height of irony for McLaughlin and Blish, who initiated the study because they’d seen reports suggesting, although not proving, that ACE2 might be present in fat tissue. (Nobody had claimed to have sighted the protein itself, Blish added.)

But the researchers found, to their surprise, that ACE2 was virtually nonexistent on cells present in fat tissue.

“It’s highly unlikely the virus is entering through ACE2, because we couldn’t detect the functional protein in adipose tissue,” said Blish.

That means clearing SARS-CoV-2 from fat tissue could require new drugs. Monoclonal antibody therapies licensed for COVID-19, for instance, generally work by interfering with ACE2/SARS-CoV-2 interaction.

Fat tissue’s potential to serve as a reservoir where SARS-CoV-2 can hide out also raises the possibility that it could contribute to the enduring post-infection symptoms collectively called long COVID, a hypothesis that McLaughlin and Blish are beginning to explore.

Researchers from the University of Tübingen, University of Basel, Beth Israel Deaconess Medical Center in Boston and Cantonal Hospital Baselland in Liestal, Switzerland contributed to the work.

The study was funded by the National Institutes of Health (grants R21AI159024, 5T32 AI007502 and T32 DK007217), the American Diabetes Association, the Stanford University Innovative Medicines Accelerator, the Botnar Research Centre for Child Health, the Swiss National Science Foundation, the Chan Zuckerberg Biohub, the National Science Foundation and the Bill and Melinda Gates Foundation.